化学辐射疗法加免疫疗法治疗局部发达鼻癌:一个成本效益分析
Kun Liu1, Youwen Zhu1, Shan Li1,2
1Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Head & neck
|September 9, 2024
概括
将辛蒂利马布添加到化疗放射治疗中,可以改善晚期鼻癌 (NPC) 患者的存活率. 这种组合疗法在中国是一个具有成本效益的治疗选择,具有显著的价值.
科学领域:
- 在瘤学瘤学.
- 辐射疗法 辐射疗法
- 药物经济学 药物经济学
背景情况:
- 免疫检查点抑制剂 (ICI) 与放射治疗相结合,在癌症治疗中显示出更好的疗效.
- 晚期鼻癌 (NPC) 患者受益于免疫疗法与化学放射治疗相结合,延长存活时间.
- 药物经济评估对于临床采用新型癌症治疗方案至关重要.
研究的目的:
- 评估添加sintilimab的成本效益,以化学辐射疗法在中国的locoregionally先进的NPC.
- 为了比较sintilimab加化学辐射疗法与单独化学辐射疗法的经济和健康益处.
主要方法:
- 一个三态马尔科夫模型是使用3期CONTINUUM试验数据开发的.
- 成本效益分析比较了化疗放射治疗加上辛蒂利马布与标准化疗放射治疗.
- 结果包括增量成本效益比率 (ICER),净货币收益 (INMB) 和净健康收益 (INHB) 在支付意愿 (WTP) 门.
主要成果:
- 与标准组相比,Sintilimab组的总成本 (92,116美元) 较高,但产品质量调整寿命年 (QALYs) (6.68) 比标准组 (53,255美元;3.75QALYs) 更多.
- 增量成本效益比 (ICER) 为13,230美元/QALY,增量净货币效益 (INMB) 在WTP值为70,021美元.
- 在90.55%的模拟中,Sintilimab加化学辐射疗法被青,这表明它在中国的成本效益.
结论:
- 在化学放射治疗中添加辛蒂利马布是一种创新且具有成本效益的策略,用于在中国管理局部或地区先进的NPC.
- 这种组合疗法为NPC患者提供了显著的价值和改善的结果.
相关概念视频
Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K


